918524-63-7

Basic information

• Product Name: 1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE
• Synonyms: 1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE;1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine HCl;2-(4-Methylpiperazino)pyridine-5-boronic acid pinacol ester;1-Methyl-4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]piperazine, 2-(4-Methylpiperazin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine;Piperazine, 1-Methyl-4-[5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]-;6-(4-Methylpiperazin-1-yl)pyridin-3-ylboronic acid pinacol ester;6-(4-Methyl-1-piperazinyl)pyridine-3-boronic Acid Pinacol Ester;2-(4-Methylpiperazino)pyridine-5-boronic acid pinacol ester 2-(4-Methylpiperazin-1-yl)pyridine-5-boronic acid pinacol ester
• CAS NO: 918524-63-7
• Molecular Formula: C₁₆H₂₆BN₃O₂
• Molecular Weight: 303.20754
• Mol File: 918524-63-7.mol

Chemical Properties

• Melting Point: 125 °C
• Boiling Point: 435.2°C at 760 mmHg
• Flash Point: 217°C
• Appearance: /
• Density: 1.1g/cm³
• Vapor Pressure: 8.95E-08mmHg at 25°C
• Refractive Index: 1.542
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.41±0.31(Predicted)
• CAS DataBase Reference: 1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE(918524-63-7)
• EPA Substance Registry System: 1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE(918524-63-7)

Safety Data

• Hazard Codes: C
• Statements: 22-34
• Safety Statements: 22-26-36/37/39-45
• TSCA: No
• Hazardous Substances Data: 918524-63-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H26BN3O2/c1-15(2)16(3,4)22-17(21-15)13-6-7-14(18-12-13)20-10-8-19(5)9-11-20/h6-7,12H,8-11H2,1-5H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 624-28-2 2,5-dibromopyridine 
• 73183-34-3 bis(pinacol)diborane 
• 364794-58-1 1-N-(5-bromopyridin-2-yl)-4-methylpiperazine 
• 123-91-1 1,4-dioxane 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 1040539-92-1 N-{[5-hydroxy-6-(1-methylethyl)-2-({4-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]phenyl}methyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine 
• 1040541-06-7 N-{[5-hydroxy-6-(1-methylethyl)-2-({3-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]phenyl}methyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine 
• 957194-91-1 1-(5-chloro-2-trifluoromethyl-benzyl)-7-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine 
• 957194-86-4 2-(2,5-difluoro-phenyl)-1-{7-[2-(4-methylpiperazin-1-yl)-pyridin-4-yl]-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-1-yl}-ethanone 
• 1333492-70-8 6'-(4-methylpiperazin-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-2,3'-bipyridine 
• 1346572-63-1 GSK503 
• 1469858-60-3 6-(4-methoxyphenyl)-2-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-4-(2-trimethylsilanylethoxymethyl)-4,7-dihydro-1-thia-4,5-diazacyclopenta[a]pentalene 
• 1476076-17-1 N-(2-(2-methoxyphenyl)propyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrimidin-4-amine 
• 1416000-00-4 2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 

Relevant articles and documents

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF

The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.

EZH2 INHIBITORS AND USES THEREOF

The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors.

PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The invention provides a family of 1,4-benzodiazepinone compounds and methods for their use as therapeutic agents in treating cancer. Pharmaceutical compositions and methods of making the 1,4-benzodiazepinone compounds are provided.

BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R6, A and Y are as defined in the specification, as inhibitors of (MK2 or MAPKAP kinase-2).